# 24-hour Efficacy of AR-12286

> **NCT01330979** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** AR-12286 0.5% Ophthalmic Solution

## Key facts

- **NCT ID:** NCT01330979
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01330979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01330979, "24-hour Efficacy of AR-12286". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01330979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*